Diabetes Clinical Trials in North Carolina

Showing 401-420 of 612 trials

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

NCT01933672

Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes

Type 2 Diabetes Mellitus

Pfizer33 participantsStarted Oct 2013

DeLand, Florida, United States • South Miami, Florida, United States • South Miami, Florida, United States +5 more locations

COMPLETEDPhase 331 miles

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

NCT00717457

This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared with exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both. Patients will be randomized to receive taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly) or exenatide (5 micrograms twice daily for 4 weeks followed by 10 micrograms twice daily) in a ratio of 1:1:1 in addition to continued prestudy metformin and thiazolidinedione either alone or in combination. The anticipated time on study treatment is 3+ years, and the target sample size is \>500 individuals.

Diabetes Mellitus Type 2

Hoffmann-La Roche1,189 participantsStarted Jul 2008

Haleyville, Alabama, United States • Mobile, Alabama, United States • Montgomery, Alabama, United States +213 more locations

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Diabetes Trials in Other Cities

A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

A Study of Aleglitazar in Patients With Type 2 Diabetes

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

T and B Cell Responses in Autoimmune Diseases

Connecting Smartphones With Electronic Health Record to Facilitate Behavioral Goal Monitoring in Diabetes Care

Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors

In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Other Conditions in North Carolina